IRLAB Therapeutics has announced the publication of preclinical data on mesdopetam in the prestigious peer-reviewed journal, European Journal of Neuroscience. The research provided insights into the mechanisms behind the antidyskinetic properties of mesdopetam, as well as its potential to address psychosis in Parkinson’s disease patients.
Mesdopetam is IRLAB’s lead clinical asset. Provided the company secures a suitable partner, a Phase III programme in levodopa-induced dyskinesias could be launched within 2025.
Consumer | Comment
Healthcare | Comment
Industrials | Comment
TMT | Comment
Industrials | Comment